---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-23-000035"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T12:29:32.359261+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pacira Q2 net income $25.8M; EXPAREL guidance cut to $550-560M

## Summary
- Total revenue $169.5M flat YoY; EXPAREL net sales $135.1M down from $137.0M.
- GAAP net income $25.8M ($0.51 diluted EPS) vs $19.9M ($0.40) YoY; adjusted EBITDA $54.3M.
- Lowers FY2023 EXPAREL guidance to $550-560M from $570-580M; ZILRETTA to $110-115M.
- Cash $220.8M; operating cash flow $43.5M vs $29.8M YoY.
- Non-GAAP gross margin guidance cut to 73-74% from prior 76-78%.

## SEC filing metadata
- accession: 0001396814-23-000035
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000035/0001396814-23-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000035/pcrx-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-23-000035
- JSON: https://secwatch.observer/filing/0001396814-23-000035.json
- Plain text: https://secwatch.observer/filing/0001396814-23-000035.txt

## Key facts
- Earnings Releases
  Pacira BioSciences, Inc. reported the second quarter ended June 30, 2023 results: revenue Total revenues of $169.5 million, net income Net income of $25.8 million, EPS $0.56 per share (basic) and $0.51 per share (diluted). Guidance lowered.
  - Period: the second quarter ended June 30, 2023
  - Revenue: Total revenues of $169.5 million
  - Net income: Net income of $25.8 million
  - EPS: $0.56 per share (basic) and $0.51 per share (diluted)
  - Guidance: lowered
  - Result: reported results
  source text: Total revenues of $169.5 million • Net product sales of $135.1 million for EXPAREL, $29.3 million for ZILRETTA, and $4.4 million for iovera° • Net income of $25.8 million, or $0.56 per share (basic) and $0.51 per share (diluted)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000035/0001396814-23-000035-index.htm
- Earnings Releases
  Pacira BioSciences, Inc. updated its full year 2023 guidance (lowered).
  - Period: full year 2023
  - Guidance: lowered
  - Result: guidance update
  source text: Pacira is revising the following full-year financial guidance: • EXPAREL net product sales of $550 million to $560 million versus the company’s previously guided range of $570 million to $580 million; • ZILRETTA net product sales of $110 million to $115 million versus the company’s previously guided range of $115 million to $125 million; • Non-GAAP gross margin of 73% to 74% versus the company’s previously guided range of 76% to 78%; and • Stock-based compensation of $46 million to $49 million versus the company’s previously guided range of $51 million to $54 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681423000035/0001396814-23-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.